C

China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062

Watchlist Manager
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Watchlist
Price: 20.8 CNY -6.47% Market Closed
Market Cap: 21.4B CNY
Have any thoughts about
China Resources Double-Crane Pharmaceutical Co Ltd?
Write Note

Intrinsic Value

The intrinsic value of one China Resources Double-Crane Pharmaceutical Co Ltd stock under the Base Case scenario is 34.08 CNY. Compared to the current market price of 20.8 CNY, China Resources Double-Crane Pharmaceutical Co Ltd is Undervalued by 39%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
34.08 CNY
Undervaluation 39%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation Backtest
China Resources Double-Crane Pharmaceutical Co Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for China Resources Double-Crane Pharmaceutical Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about China Resources Double-Crane Pharmaceutical Co Ltd?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
China Resources Double-Crane Pharmaceutical Co Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about China Resources Double-Crane Pharmaceutical Co Ltd

Provide an overview of the primary business activities
of China Resources Double-Crane Pharmaceutical Co Ltd.

What unique competitive advantages
does China Resources Double-Crane Pharmaceutical Co Ltd hold over its rivals?

What risks and challenges
does China Resources Double-Crane Pharmaceutical Co Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide P/S
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide P/E
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide P/OCF
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide P/FCFE
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide P/B
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide EV/S
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide EV/GP
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide EV/EBITDA
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide EV/EBIT
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide EV/OCF
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide EV/FCFF
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide EV/IC
for China Resources Double-Crane Pharmaceutical Co Ltd.

Show me price targets
for China Resources Double-Crane Pharmaceutical Co Ltd made by professional analysts.

What are the Revenue projections
for China Resources Double-Crane Pharmaceutical Co Ltd?

How accurate were the past Revenue estimates
for China Resources Double-Crane Pharmaceutical Co Ltd?

What are the Net Income projections
for China Resources Double-Crane Pharmaceutical Co Ltd?

How accurate were the past Net Income estimates
for China Resources Double-Crane Pharmaceutical Co Ltd?

What are the EPS projections
for China Resources Double-Crane Pharmaceutical Co Ltd?

How accurate were the past EPS estimates
for China Resources Double-Crane Pharmaceutical Co Ltd?

What are the EBIT projections
for China Resources Double-Crane Pharmaceutical Co Ltd?

How accurate were the past EBIT estimates
for China Resources Double-Crane Pharmaceutical Co Ltd?

Compare the revenue forecasts
for China Resources Double-Crane Pharmaceutical Co Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of China Resources Double-Crane Pharmaceutical Co Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of China Resources Double-Crane Pharmaceutical Co Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of China Resources Double-Crane Pharmaceutical Co Ltd compared to its peers.

Compare the P/E ratios
of China Resources Double-Crane Pharmaceutical Co Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing China Resources Double-Crane Pharmaceutical Co Ltd with its peers.

Analyze the financial leverage
of China Resources Double-Crane Pharmaceutical Co Ltd compared to its main competitors.

Show all profitability ratios
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide ROE
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide ROA
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide ROIC
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide ROCE
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide Gross Margin
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide Operating Margin
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide Net Margin
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide FCF Margin
for China Resources Double-Crane Pharmaceutical Co Ltd.

Show all solvency ratios
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide D/E Ratio
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide D/A Ratio
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide Interest Coverage Ratio
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide Altman Z-Score Ratio
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide Quick Ratio
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide Current Ratio
for China Resources Double-Crane Pharmaceutical Co Ltd.

Provide Cash Ratio
for China Resources Double-Crane Pharmaceutical Co Ltd.

What is the historical Revenue growth
over the last 5 years for China Resources Double-Crane Pharmaceutical Co Ltd?

What is the historical Net Income growth
over the last 5 years for China Resources Double-Crane Pharmaceutical Co Ltd?

What is the current Free Cash Flow
of China Resources Double-Crane Pharmaceutical Co Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for China Resources Double-Crane Pharmaceutical Co Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
China Resources Double-Crane Pharmaceutical Co Ltd

Current Assets 7.1B
Cash & Short-Term Investments 2.3B
Receivables 3B
Other Current Assets 1.9B
Non-Current Assets 9B
Long-Term Investments 1.1B
PP&E 4.2B
Intangibles 3.4B
Other Non-Current Assets 159.1m
Current Liabilities 4.9B
Accounts Payable 775.5m
Accrued Liabilities 1.8B
Short-Term Debt 125m
Other Current Liabilities 2.2B
Non-Current Liabilities 1.3B
Long-Term Debt 129.5m
Other Non-Current Liabilities 1.2B
Efficiency

Earnings Waterfall
China Resources Double-Crane Pharmaceutical Co Ltd

Revenue
11.2B CNY
Cost of Revenue
-4.9B CNY
Gross Profit
6.3B CNY
Operating Expenses
-4.7B CNY
Operating Income
1.7B CNY
Other Expenses
-2.3m CNY
Net Income
1.7B CNY

Free Cash Flow Analysis
China Resources Double-Crane Pharmaceutical Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

China Resources Double-Crane Pharmaceutical Co Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
59/100
Profitability
Score

China Resources Double-Crane Pharmaceutical Co Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

China Resources Double-Crane Pharmaceutical Co Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
High Altman Z-Score
Long-Term Solvency
75/100
Solvency
Score

China Resources Double-Crane Pharmaceutical Co Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
China Resources Double-Crane Pharmaceutical Co Ltd

Wall Street analysts forecast China Resources Double-Crane Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for China Resources Double-Crane Pharmaceutical Co Ltd is 27.46 CNY with a low forecast of 25.25 CNY and a high forecast of 31.25 CNY.

Lowest
Price Target
25.25 CNY
21% Upside
Average
Price Target
27.46 CNY
32% Upside
Highest
Price Target
31.25 CNY
50% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for China Resources Double-Crane Pharmaceutical Co Ltd?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for China Resources Double-Crane Pharmaceutical Co Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

China Resources Double-Crane Pharmaceutical Co Ltd

Country

China

Industry

Pharmaceuticals

Market Cap

21.4B CNY

Dividend Yield

0%

Description

China Resources Double-Crane Pharmaceutical Co., Ltd. engages in the processing, manufacture, and sale of pharmaceutical, chemical, and biomedical raw materials. The company is headquartered in Beijing, Beijing and currently employs 11,029 full-time employees. is a China-based company principally engaged in the development, manufacture and distribution of pharmaceuticals. The firm's main businesses are classified into three segments: Chronic Disease segment, Specialist segment and Infusion segment. Chronic Disease segment mainly provides products for lowering blood pressure, blood fat and blood glucose. Specialist segment mainly involves in the research, development and distribution of pharmaceuticals targeting six areas, including cardiovascular and cerebrovascular, pediatrics, kidney disease, mental/nerve, anesthesia and analgesia and respiratory areas. Infusion segment various types of infusion products, such as basic infusion, therapeutic infusion and nutritional. The firm distributes its products mainly in domestic market.

Contact

BEIJING
Beijing
No.1 Lize East Er Road, Wangjing, Chaoyang District
+861064398099
www.dcpc.com

IPO

1997-05-22

Employees

11 029

Officers

Chairman of the Board & Acting President
Mr. Wenchao Lu
VP & Company Secretary
Mr. Hekai Tan
Vice President
Ms. Donghan Yao
Chief Financial Officer
Mr. Ju Liu

See Also

Discover More
What is the Intrinsic Value of one China Resources Double-Crane Pharmaceutical Co Ltd stock?

The intrinsic value of one China Resources Double-Crane Pharmaceutical Co Ltd stock under the Base Case scenario is 34.08 CNY.

Is China Resources Double-Crane Pharmaceutical Co Ltd stock undervalued or overvalued?

Compared to the current market price of 20.8 CNY, China Resources Double-Crane Pharmaceutical Co Ltd is Undervalued by 39%.

Back to Top